The FAPI Fibrosis Study
Research type
Research Study
Full title
PROline and FapI with Late gadolinium Enhancement in Myocardial Infarction (PROFILE - MI) "The FAPI Fibrosis study"
IRAS ID
262477
Contact name
Evangelos Tzolos
Contact email
Duration of Study in the UK
3 years, 0 months, 8 days
Research summary
We aim to examine whether 68Ga-FAPI or 18F-AlF-FAPI[(radiotracer(a colourless liquid injected in order to take the pictures)that binds in active collagen)] can be used to quantify the fibrosis process (scarring) which is a process that affects various common conditions including heart attacks and aortic stenosis (narrowed valve). In particular, fibrosis appears to be the common final pathway of injury in the myocardium (heart muscle), underlying almost every heart condition.
68Ga-FAPI and 18F-AlF-FAPI analogues have been already been used safely in humans demonstrating acceptable radiation doses. In studies including patients with various cancers, 68Ga-FAPI and 18F-AlF-FAPI proved to be really good tracers for imaging of active scarring.
In this study we are going to explore whether fibrosis activity is increased compared to healthy controls in the affected and healthy myocardium following myocardial infarction and to establish the time point of maximal fibrosis activity in these areas. We also aim to look at blood vessel fibrosis activity in aortic atherosclerosis (plaque disease) in patients with stable and unstable coronary (heart blood vessels) atherosclerosis (plaque in the arteries).
REC name
South East Scotland REC 02
REC reference
20/SS/0023
Date of REC Opinion
6 Mar 2020
REC opinion
Further Information Favourable Opinion